PDF(Pubmed)
Abstract：
UNASSIGNED: Salivary gland tumours are rare cancers with variable course and prognosis. There is a paucity of data, especially for the advanced stages.
UNASSIGNED: This is a retrospective analysis carried out in our institute. All patients seeking treatment for incurable advanced salivary gland tumours from October 2018 to September 2022 were included. Relevant clinical data were collected and appropriate statistical analysis was applied.
UNASSIGNED: 30 patients were included in the analysis. The parotid gland was the most common site of origin (73%). Adenoid cystic carcinoma (ACC) and salivary duct carcinoma (SDC) were equally (37%) the most common pathological subtypes. The majority of patients were males (73%) and lungs (57%) were the most common site of metastases. On molecular analysis, SDC had high rates of androgen receptor (AR) (90%) and human epidermal growth factor receptor 2 (HER2) (55%) positivity. Mucoepidermoid carcinoma (MEC) had AR and HER2 positivity rates of 17% and 20%, respectively, while for ACC it was even lower. A variety of treatment regimens including hormonal therapy, anti-HER2 targeted therapy and chemotherapy were used in first-line treatment. With an overall response rate (ORR) of 10/21 (48%), only 9/21 (43%) went on to receive second-line treatment with an ORR of 4/9 (44%). The progression-free survival (PFS) with first-line treatment (PFS1) was a median of 5 months. The median PFS1 was worst for MEC. The median overall survival (OS) was 10 months. Median OS for ACC, SDC and MEC were 11, 10 and 7 months, respectively. At 24 months, ACC had much higher survival (50%) than others (10%) indicating a proportion of ACC with an indolent course.
UNASSIGNED: Our analysis highlights the variable disease biology of advanced salivary gland tumours and throws light on the various possible treatment targets and strategies. Molecular profiling and advancement in targeted therapies are expected to increase survival in this group of rare cancers.
UNASSIGNED: This is a retrospective analysis carried out in our institute. All patients seeking treatment for incurable advanced salivary gland tumours from October 2018 to September 2022 were included. Relevant clinical data were collected and appropriate statistical analysis was applied.
UNASSIGNED: 30 patients were included in the analysis. The parotid gland was the most common site of origin (73%). Adenoid cystic carcinoma (ACC) and salivary duct carcinoma (SDC) were equally (37%) the most common pathological subtypes. The majority of patients were males (73%) and lungs (57%) were the most common site of metastases. On molecular analysis, SDC had high rates of androgen receptor (AR) (90%) and human epidermal growth factor receptor 2 (HER2) (55%) positivity. Mucoepidermoid carcinoma (MEC) had AR and HER2 positivity rates of 17% and 20%, respectively, while for ACC it was even lower. A variety of treatment regimens including hormonal therapy, anti-HER2 targeted therapy and chemotherapy were used in first-line treatment. With an overall response rate (ORR) of 10/21 (48%), only 9/21 (43%) went on to receive second-line treatment with an ORR of 4/9 (44%). The progression-free survival (PFS) with first-line treatment (PFS1) was a median of 5 months. The median PFS1 was worst for MEC. The median overall survival (OS) was 10 months. Median OS for ACC, SDC and MEC were 11, 10 and 7 months, respectively. At 24 months, ACC had much higher survival (50%) than others (10%) indicating a proportion of ACC with an indolent course.
UNASSIGNED: Our analysis highlights the variable disease biology of advanced salivary gland tumours and throws light on the various possible treatment targets and strategies. Molecular profiling and advancement in targeted therapies are expected to increase survival in this group of rare cancers.
摘要：
■唾液腺肿瘤是罕见的癌症，具有不同的病程和预后。数据很少，尤其是高级阶段。
■这是我们研究所进行的回顾性分析。包括2018年10月至2022年9月寻求治疗无法治愈的晚期唾液腺肿瘤的所有患者。收集相关临床数据并进行适当的统计分析。
■30例患者纳入分析。腮腺是最常见的起源部位（73％）。腺样囊性癌（ACC）和涎管癌（SDC）是同等（37％）最常见的病理亚型。大多数患者是男性（73％），肺部（57％）是最常见的转移部位。关于分子分析，SDC的雄激素受体（AR）阳性率高（90％），人表皮生长因子受体2（HER2）阳性率高（55％）。粘液表皮样癌（MEC）的AR和HER2阳性率分别为17％和20％，分别,而ACC则更低。各种治疗方案，包括激素治疗，抗HER2靶向治疗和化疗用于一线治疗.总反应率（ORR）为10/21（48%），只有9/21(43%)继续接受二线治疗,ORR为4/9(44%).一线治疗（PFS1）的无进展生存期（PFS）的中位数为5个月。MEC的PFS1中位数最差。中位总生存期(OS)为10个月。ACC的中位操作系统，SDC和MEC分别为11、10和7个月，分别。24个月时,ACC的生存率（50％）比其他生存率（10％）高得多，表明ACC的比例缓慢。
■我们的分析强调了晚期唾液腺肿瘤的可变疾病生物学特性，并阐明了各种可能的治疗目标和策略。分子谱分析和靶向治疗的进步有望增加这组罕见癌症的生存率。
■这是我们研究所进行的回顾性分析。包括2018年10月至2022年9月寻求治疗无法治愈的晚期唾液腺肿瘤的所有患者。收集相关临床数据并进行适当的统计分析。
■30例患者纳入分析。腮腺是最常见的起源部位（73％）。腺样囊性癌（ACC）和涎管癌（SDC）是同等（37％）最常见的病理亚型。大多数患者是男性（73％），肺部（57％）是最常见的转移部位。关于分子分析，SDC的雄激素受体（AR）阳性率高（90％），人表皮生长因子受体2（HER2）阳性率高（55％）。粘液表皮样癌（MEC）的AR和HER2阳性率分别为17％和20％，分别,而ACC则更低。各种治疗方案，包括激素治疗，抗HER2靶向治疗和化疗用于一线治疗.总反应率（ORR）为10/21（48%），只有9/21(43%)继续接受二线治疗,ORR为4/9(44%).一线治疗（PFS1）的无进展生存期（PFS）的中位数为5个月。MEC的PFS1中位数最差。中位总生存期(OS)为10个月。ACC的中位操作系统，SDC和MEC分别为11、10和7个月，分别。24个月时,ACC的生存率（50％）比其他生存率（10％）高得多，表明ACC的比例缓慢。
■我们的分析强调了晚期唾液腺肿瘤的可变疾病生物学特性，并阐明了各种可能的治疗目标和策略。分子谱分析和靶向治疗的进步有望增加这组罕见癌症的生存率。
